Evoke Pharma Total Change in Assets/Liabilities 2012-2024 | EVOK
Evoke Pharma total change in assets/liabilities from 2012 to 2024. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
Evoke Pharma Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-1 |
| 2023 |
$1 |
| 2022 |
$0 |
| 2021 |
$-6 |
| 2020 |
$5 |
| 2019 |
$-0 |
| 2018 |
$-1 |
| 2017 |
$1 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$1 |
| 2013 |
$-0 |
| 2012 |
$0 |
| 2011 |
$-1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.010B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
